The Role of Osteopontin Expression in Melanoma Progression
Overview
Authors
Affiliations
It was shown that osteopontin (OPN), a glycophosphoprotein, plays divergent roles in cancer progression. In addition to multiple intra- and extracellular functions, it facilitates migration of tumour cells, has crucial role in cell adhesion and is associated with increased metastasis formation. In previous studies, we performed global gene expression profiling on a series of primary melanoma samples and found that OPN was significantly overexpressed in ulcerated melanomas. The major purpose of this study was to define OPN expression in primary melanomas with differing biological behaviours. OPN mRNA expression was analysed by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in primary melanoma tissues. Immunohistochemistry was performed using a tissue microarray. Cox regression tests were used for survival analysis. Greater than 50 % of the tissues exhibited high protein expression that was significantly associated with tumour thickness and metastasis. OPN mRNA expression was significantly increased in thicker melanomas and lesions with an ulcerated surface. Increased expression was primarily detected in advanced-stage tumours. A multivariate Cox regression analysis revealed that high OPN expression, tumour thickness and metastasis were significantly associated with reduced relapse-free survival. In summary, high OPN mRNA and protein expression were associated with a less favourable clinical outcome of primary melanoma patients. We determined that OPN is a significant predictive factor for the survival of primary melanoma patients. Based on our and others data, the high expression of OPN may have a crucial stimulatory role in tumour progression and metastasis formation, which, thus, have been proposed as potential targets for cancer diagnosis and therapy.
Levati L, Tabolacci C, Facchiano A, Facchiano F, Alvino E, Antonini Cappellini G J Exp Clin Cancer Res. 2024; 43(1):226.
PMID: 39143551 PMC: 11325673. DOI: 10.1186/s13046-024-03151-3.
Combining Biomarkers for the Diagnosis of Metastatic Melanoma.
Varvolgyi T, Janka E, Szasz I, Koroknai V, Toka-Farkas T, Szabo I J Clin Med. 2024; 13(1).
PMID: 38202181 PMC: 10779676. DOI: 10.3390/jcm13010174.
Thrombin Cleavage of Osteopontin and the Host Anti-Tumor Immune Response.
Leung L, Myles T, Morser J Cancers (Basel). 2023; 15(13).
PMID: 37444590 PMC: 10340489. DOI: 10.3390/cancers15133480.
Saup R, Nair N, Shen J, Schmaus A, Thiele W, Garvalov B Biomedicines. 2023; 11(4).
PMID: 37189656 PMC: 10135562. DOI: 10.3390/biomedicines11041038.
Gene Expression Patterns of Osteopontin Isoforms and Integrins in Malignant Melanoma.
Jambor K, Koroknai V, Kiss T, Szasz I, Piko P, Balazs M Pathol Oncol Res. 2022; 28:1610608.
PMID: 36091936 PMC: 9448871. DOI: 10.3389/pore.2022.1610608.